David C Rees

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8927095/publications.pdf

Version: 2024-02-01

219 papers	10,751 citations	50273 46 h-index	37202 96 g-index
226 all docs	226 docs citations	226 times ranked	9871 citing authors

#	Article	IF	Citations
1	Sickle-cell disease. Lancet, The, 2010, 376, 2018-2031.	13.7	1,794
2	Sickle Cell Disease. New England Journal of Medicine, 2017, 376, 1561-1573.	27.0	898
3	Global distribution of the CCR5 gene 32-basepair deletion. Nature Genetics, 1997, 16, 100-103.	21.4	512
4	Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria. New England Journal of Medicine, 2020, 382, 2289-2301.	27.0	350
5	FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. British Journal of Haematology, 2000, 111, 190-195.	2.5	257
6	Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Human Genetics, 2002, 111, 360-367.	3.8	251
7	Novel mutations in PIEZO1 cause an autosomal recessive generalized lymphatic dysplasia with non-immune hydrops fetalis. Nature Communications, 2015, 6, 8085.	12.8	247
8	Worldwide Distribution of a Common Methylenetetrahydrofolate Reductase Mutation. American Journal of Human Genetics, 1998, 62, 1258-1260.	6.2	230
9	Significant haemoglobinopathies: guidelines for screening and diagnosis. British Journal of Haematology, 2010, 149, 35-49.	2.5	230
10	Guidelines for the management of the acute painful crisis in sickle cell disease. British Journal of Haematology, 2003, 120, 744-752.	2.5	209
11	The Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) study: a randomised, controlled, multicentre clinical trial. Lancet, The, 2013, 381, 930-938.	13.7	209
12	Phase 1 Trial of an RNA Interference Therapy for Acute Intermittent Porphyria. New England Journal of Medicine, 2019, 380, 549-558.	27.0	194
13	The spleen and sickle cell disease: the sick(led) spleen. British Journal of Haematology, 2014, 166, 165-176.	2.5	192
14	The Population Genetics of Factor V Leiden (Arg506Gln). British Journal of Haematology, 1996, 95, 579-586.	2.5	181
15	Acute haemolysis induced by high dose ascorbic acid in glucose-6-phosphate dehydrogenase deficiency.. BMJ: British Medical Journal, 1993, 306, 841-842.	2.3	167
16	Stomatocytic haemolysis and macrothrombocytopenia (Mediterranean) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 Td (stomatocytosis/m British Journal of Haematology, 2005, 130, 297-309.	2.5	138
17	Recommendations regarding splenectomy in hereditary hemolytic anemias. Haematologica, 2017, 102, 1304-1313.	3.5	138
18	Update review of the acute porphyrias. British Journal of Haematology, 2017, 176, 527-538.	2.5	133

#	Article	IF	Citations
19	A Multinational Trial of Prasugrel for Sickle Cell Vaso-Occlusive Events. New England Journal of Medicine, 2016, 374, 625-635.	27.0	117
20	Molecular Analysis of the Î²-Globin Gene Cluster in the Niokholo Mandenka Population Reveals a Recent Origin of the Î²S Senegal Mutation. American Journal of Human Genetics, 2002, 70, 207-223.	6.2	115
21	EXPLORE: A Prospective, Multinational, Natural History Study of Patients with Acute Hepatic Porphyria with Recurrent Attacks. Hepatology, 2020, 71, 1546-1558.	7.3	103
22	Born to clot: the European burden. British Journal of Haematology, 1999, 105, 564-566.	2.5	100
23	Biomarkers in sickle cell disease. British Journal of Haematology, 2012, 156, 433-445.	2.5	100
24	Best practice guidelines on clinical management of acute attacks of porphyria and their complications. Annals of Clinical Biochemistry, 2013, 50, 217-223.	1.6	96
25	Environmental determinants of severity in sickle cell disease. Haematologica, 2015, 100, 1108-1116.	3.5	90
26	The Hemoglobin E Syndromes. Annals of the New York Academy of Sciences, 1998, 850, 334-343.	3.8	89
27	Haptoglobin-related protein is a high-affinity hemoglobin-binding plasma protein. Blood, 2006, 108, 2846-2849.	1.4	89
28	Deoxygenation-induced and Ca2+ dependent phosphatidylserine externalisation in red blood cells from normal individuals and sickle cell patients. Cell Calcium, 2012, 51, 51-56.	2.4	78
29	Regression of extramedullary haemopoiesis and augmentation of fetal haemoglobin concentration during hydroxyurea therapy in Î² thalassaemia. British Journal of Haematology, 1998, 101, 416-419.	2.5	74
30	Alpha thalassaemia is associated with increased soluble transferrin receptor levels. British Journal of Haematology, 1998, 103, 365-369.	2.5	72
31	The metabolites of nitric oxide in sickle-cell disease. British Journal of Haematology, 1995, 91, 834-837.	2.5	69
32	Audit of the Use of Regular Haem Arginate Infusions in Patients with Acute Porphyria to Prevent Recurrent Symptoms. JIMD Reports, 2015, 22, 57-65.	1.5	65
33	Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet, The, 1997, 350, 491-492.	13.7	63
34	Windy weather and low humidity are associated with an increased number of hospital admissions for acute pain and sickle cell disease in an urban environment with a maritime temperate climate. British Journal of Haematology, 2005, 131, 530-533.	2.5	61
35	Genetic basis of hemolytic anemia caused by pyrimidine 5â€² nucleotidase deficiency. Blood, 2001, 97, 3327-3332.	1.4	59
36	Temporal relationship of asthma to acute chest syndrome in sickle cell disease. Pediatric Pulmonology, 2007, 42, 103-106.	2.0	59

#	Article	IF	Citations
37	Evidence for a single origin of factor V Leiden. British Journal of Haematology, 1996, 92, 1022-1025.	2.5	57
38	Auto-adjusting positive airway pressure in children with sickle cell anemia: results of a phase I randomized controlled trial. Haematologica, 2009, 94, 1006-1010.	3.5	57
39	Pyrimidine 5â€² Nucleotidase Deficiency. British Journal of Haematology, 2003, 120, 375-383.	2.5	56
40	Impact of acute chest syndrome on lung function of children with sickle cell disease. Journal of Pediatrics, 2006, 149, 17-22.	1.8	56
41	Addressing the diagnostic gaps in pyruvate kinase deficiency: Consensus recommendations on the diagnosis of pyruvate kinase deficiency. American Journal of Hematology, 2019, 94, 149-161.	4.1	55
42	Age-related changes in adaptation to severe anemia in childhood in developing countries. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 9440-9444.	7.1	54
43	Management of sickle cell disease in the community. BMJ, The, 2014, 348, g1765-g1765.	6.0	51
44	End points for sickle cell disease clinical trials: patient-reported outcomes, pain, and the brain. Blood Advances, 2019, 3, 3982-4001.	5.2	51
45	Urinary excretion of porphyrins, porphobilinogen and Î´-aminolaevulinic acid following an attack of acute intermittent porphyria. Journal of Clinical Pathology, 2014, 67, 60-65.	2.0	50
46	Lamin Bâ€receptor mutations in Pelgerâ€“HuÃ«t anomaly. British Journal of Haematology, 2003, 123, 542-544.	2.5	49
47	Extracranial internal carotid arterial disease in children with sickle cell anemia. Haematologica, 2010, 95, 1287-1292.	3.5	48
48	Elimination of Transfusions Through Induction of Fetal Hemoglobin Synthesis in Cooley's Anemia^a. Annals of the New York Academy of Sciences, 1998, 850, 100-109.	3.8	47
49	Erythroblastic Inclusions in Dominantly Inherited Î² Thalassemias. Blood, 1997, 89, 322-328.	1.4	45
50	Trials in Sickle Cell Disease. Pediatric Neurology, 2006, 34, 450-458.	2.1	44
51	Airway hyperresponsiveness and acute chest syndrome in children with sickle cell anemia. Pediatric Pulmonology, 2007, 42, 272-276.	2.0	42
52	Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients. Haematologica, 2020, 105, 2651-2654.	3.5	42
53	Longitudinal assessment of lung function in children with sickle cell disease. Pediatric Pulmonology, 2016, 51, 717-723.	2.0	40
54	Parentsâ€™ Experiences of Receiving the Initial Positive Newborn Screening (NBS) Result for Cystic Fibrosis and Sickle Cell Disease. Journal of Genetic Counseling, 2016, 25, 1215-1226.	1.6	40

#	Article	IF	Citations
55	Airways obstruction and pulmonary capillary blood volume in children with sickle cell disease. Pediatric Pulmonology, 2014, 49, 716-722.	2.0	38
56	Glucose 6 phosphate dehydrogenase deficiency is not associated with cerebrovascular disease in children with sickle cell anemia. Blood, 2009, 114, 742-743.	1.4	36
57	The rationale for using hydroxycarbamide in the treatment of sickle cell disease. Haematologica, 2011, 96, 488-491.	3.5	36
58	The associations between air quality and the number of hospital admissions for acute pain and sickle-cell disease in an urban environment. British Journal of Haematology, 2007, 136, 844-848.	2.5	35
59	A Simple Index Using Age, Hemoglobin, and Aspartate Transaminase Predicts Increased Intracerebral Blood Velocity as Measured by Transcranial Doppler Scanning in Children With Sickle Cell Anemia. Pediatrics, 2008, 121, e1628-e1632.	2.1	35
60	Serum lactate dehydrogenase activity as a biomarker in children with sickle cell disease. British Journal of Haematology, 2007, 140, 071119224223004-???.	2.5	33
61	ENERCA clinical recommendations for disease management and prevention of complications of sickle cell disease in children. American Journal of Hematology, 2011, 86, 72-75.	4.1	33
62	g(HbF): a genetic model of fetal hemoglobin in sickle cell disease. Blood Advances, 2018, 2, 235-239.	5.2	33
63	Emerging therapies in sickle cell disease. British Journal of Haematology, 2020, 190, 149-172.	2.5	33
64	Exhaled carbon monoxide levels in children with sickle cell disease. European Journal of Pediatrics, 2005, 164, 162-165.	2.7	32
65	COVID-19 in patients with sickle cell disease - a case series from a UK Tertiary Hospital. Haematologica, 2020, 105, 2691-2693.	3.5	32
66	13â€valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6â€17 years of age with sickle cell disease previously vaccinated with 23â€valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study. Pediatric Blood and Cancer, 2015, 62, 1427-1436.	1.5	31
67	Are aberrant BCR-ABL transcripts more common than previously thought?. British Journal of Haematology, 2000, 111, 1109-1111.	2.5	31
68	The conductance of red blood cells from sickle cell patients: ion selectivity and inhibitors. Journal of Physiology, 2012, 590, 2095-2105.	2.9	30
69	Associations between environmental factors and hospital admissions for sickle cell disease. Haematologica, 2017, 102, 666-675.	3.5	29
70	Laboratory diagnosis of G6PD deficiency. A British Society for Haematology Guideline. British Journal of Haematology, 2020, 189, 24-38.	2.5	29
71	Reduced soluble transferrin receptor concentrations in acute malaria in Vanuatu.. American Journal of Tropical Medicine and Hygiene, 1999, 60, 875-878.	1.4	29
72	A retrospective analysis of outcome of pregnancy in patients with acute porphyria. Journal of Inherited Metabolic Disease, 2010, 33, 591-596.	3.6	28

#	Article	IF	Citations
73	Pandemic influenza A (H1N1) virus infections in children with sickle cell disease. Blood, 2010, 115, 2329-2330.	1.4	27
74	Free fetal DNA in maternal circulation: a potential prognostic marker for chromosomal abnormalities?. Prenatal Diagnosis, 2007, 27, 104-110.	2.3	26
75	Outcome of adults with sickle cell disease admitted to critical care â€“ experience of a single institution in the UK. British Journal of Haematology, 2010, 150, 610-613.	2.5	26
76	Oxidative stress and phosphatidylserine exposure in red cells from patients with sickle cell anaemia. British Journal of Haematology, 2018, 182, 567-578.	2.5	26
77	The Properties of Red Blood Cells from Patients Heterozygous for HbS and HbC (HbSC Genotype). Anemia, 2011, 2011, 1-8.	1.7	25
78	Role of Calcium in Phosphatidylserine Externalisation in Red Blood Cells from Sickle Cell Patients. Anemia, 2011, 2011, 1-8.	1.7	25
79	Acute intermittent porphyria: fatal complications of treatment. Clinical Medicine, 2012, 12, 293-294.	1.9	25
80	Nontraumatic extradural hematoma in sickle cell anemia: A rare neurological complication not to be missed. American Journal of Hematology, 2014, 89, 225-227.	4.1	25
81	Autoimmune Liver Disease in Children with Sickle Cell Disease. Journal of Pediatrics, 2017, 189, 79-85.e2.	1.8	25
82	Transcranial Doppler scanning and the assessment of stroke risk in children with haemoglobin sickle cell disease. Archives of Disease in Childhood, 2008, 93, 138-141.	1.9	23
83	Effects of 5â€hydroxymethylâ€2â€furfural on the volume and membrane permeability of red blood cells from patients with sickle cell disease. Journal of Physiology, 2014, 592, 4039-4049.	2.9	23
84	An Audit of the Use of Gonadorelin Analogues to Prevent Recurrent Acute Symptoms in Patients with Acute Porphyria in the United Kingdom. JIMD Reports, 2017, 36, 99-107.	1.5	23
85	How I manage red cell transfusions in patients with sickle cell disease. British Journal of Haematology, 2018, 180, 607-617.	2.5	23
86	Pre-Operative Transfusion Reduces Serious Adverse Events in Patients with Sickle Cell Disease (SCD): Results From the Transfusion Alternatives Preoperatively in Sickle Cell Disease (TAPS) Randomised Controlled Multicentre Clinical Trial. Blood, 2011, 118, 9-9.	1.4	23
87	Nontransfusional Iron Overload in Thalassemia: Association with Hereditary Hemochromatosis. Annals of the New York Academy of Sciences, 1998, 850, 490-494.	3.8	22
88	Ethnicity Questions and Antenatal Screening for Sickle Cell/Thalassaemia [EQUANS] in England: A Randomised Controlled Trial of Two Questionnaires. Ethnicity and Health, 2006, 11, 169-189.	2.5	22
89	Proteomic analysis of plasma from children with sickle cell anemia and silent cerebral infarction. Haematologica, 2018, 103, 1136-1142.	3.5	22
90	Lung function, transfusion, pulmonary capillary blood volume and sickle cell disease. Respiratory Physiology and Neurobiology, 2016, 222, 6-10.	1.6	21

#	Article	IF	Citations
91	The Effect of Antioxidants on the Properties of Red Blood Cells From Patients With Sickle Cell Anemia. Frontiers in Physiology, 2019, 10, 976.	2.8	21
92	Portacaths are safe for long-term regular blood transfusion in children with sickle cell anaemia. Archives of Disease in Childhood, 2011, 96, 1082-1084.	1.9	20
93	How benign is sickle cell trait?. EBioMedicine, 2016, 11, 21-22.	6.1	20
94	A gain of function variant in PIEZO1 (E756del) and sickle cell disease. Haematologica, 2019, 104, e91-e93.	3.5	20
95	Circulating DNA: a potential marker of sickle cell crisis. British Journal of Haematology, 2007, 139, 331-336.	2.5	19
96	The presence of Î±â€thalassaemia trait blunts the response to hydroxycarbamide in patients with sickle cell disease. British Journal of Haematology, 2008, 143, 589-592.	2.5	19
97	Combined blood transfusion and hydroxycarbamide in children with sickle cell anaemia. British Journal of Haematology, 2013, 160, 259-261.	2.5	19
98	Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. , 2005, , CD004450.		18
99	Hydroxyurea therapy lowers circulating DNA levels in sickle cell anemia. American Journal of Hematology, 2008, 83, 714-716.	4.1	18
100	Novel permeability characteristics of red blood cells from sickle cell patients heterozygous for HbS and HbC (HbSC genotype). Blood Cells, Molecules, and Diseases, 2010, 45, 46-52.	1.4	18
101	The clinical significance of K-Cl cotransport activity in red cells of patients with HbSC disease. Haematologica, 2015, 100, 595-600.	3.5	18
102	A survey of genetic fetal-haemoglobin modifiers in Nigerian patients with sickle cell anaemia. PLoS ONE, 2018, 13, e0197927.	2.5	18
103	Haemoglobinopathies and the rheumatologist. Rheumatology, 2016, 55, 2109-2118.	1.9	17
104	Overnight auto-adjusting continuous airway pressureâ€‰+â€‰standard care compared with standard care alone in the prevention of morbidity in sickle cell disease phase II (POMS2b): study protocol for a randomised controlled trial. Trials, 2018, 19, 55.	1.6	17
105	A randomized, placebo-controlled, double-blind trial of canakinumab in children and young adults with sickle cell anemia. Blood, 2022, 139, 2642-2652.	1.4	17
106	Red blood cell mannoses as phagocytic ligands mediating both sickle cell anaemia and malaria resistance. Nature Communications, 2021, 12, 1792.	12.8	16
107	Influence of genetic predisposition to thrombosis on natural history of acute promyelocytic leukaemia. British Journal of Haematology, 1997, 96, 490-492.	2.5	15
108	Minisatellite mutational processes reduce F st estimates. Human Genetics, 1999, 105, 567-576.	3.8	15

#	Article	IF	Citations
109	Hemoglobin F and Hemoglobin E/Î²-Thalassemia. The American Journal of Pediatric Hematology/oncology, 2000, 22, 567-572.	1.3	15
110	Heterocellular hereditary persistence of fetal haemoglobin affects the haematological parameters of Î²-thalassaemia trait. British Journal of Haematology, 2003, 123, 353-358.	2.5	15
111	Cell-free DNA levels in pregnancies at risk of sickle-cell disease and significant ethnic variation. British Journal of Haematology, 2006, 135, 738-741.	2.5	15
112	A nonâ€electrolyte haemolysis assay for diagnosis and prognosis of sickle cell disease. Journal of Physiology, 2013, 591, 1463-1474.	2.9	15
113	Vitamin D deficiency and its correction in children with sickle cell anaemia. Annals of Hematology, 2014, 93, 2051-2056.	1.8	15
114	The measurement of urinary hydroxyurea in sickle cell anaemia. British Journal of Haematology, 2005, 130, 138-144.	2.5	14
115	The effects of air quality on haematological and clinical parameters in children with sickle cell anaemia. Annals of Hematology, 2009, 88, 529-533.	1.8	14
116	Direct and simultaneous quantitation of 5â€aminolaevulinic acid and porphobilinogen in human serum or plasma by hydrophilic interaction liquid chromatographyâ€“atmospheric pressure chemical ionization/tandem mass spectrometry. Biomedical Chromatography, 2013, 27, 267-272.	1.7	14
117	Early Markers of Sickle Nephropathy in Children With Sickle Cell Anemia Are Associated With Red Cell Cation Transport Activity. HemaSphere, 2017, 1, e2.	2.7	14
118	Real-time dose adjustment using point-of-care platelet reactivity testing in a double-blind study of prasugrel in children with sickle cell anaemia. Thrombosis and Haemostasis, 2017, 117, 580-588.	3.4	14
119	Rituximab in chronic, recurrent HIV-associated immune thrombocytopenic purpura. British Journal of Haematology, 2004, 127, 607-608.	2.5	13
120	Design of the DOVE (Determining Effects of Platelet Inhibition on Vasoâ€Occlusive Events) trial: A global Phase 3 doubleâ€blind, randomized, placeboâ€controlled, multicenter study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy. Pediatric Blood and Cancer, 2016, 63, 299-305.	1.5	13
121	EHA Research Roadmap on Hemoglobinopathies and Thalassemia: An Update. HemaSphere, 2019, 3, e208.	2.7	13
122	Determinants of severity in sickle cell disease. Blood Reviews, 2022, 56, 100983.	5.7	13
123	Outcome of children with sickle cell disease admitted to intensive care â€“ a single institution experience. British Journal of Haematology, 2010, 150, 614-617.	2.5	12
124	Soluble CD163 levels in children with sickle cell disease. British Journal of Haematology, 2011, 153, 105-110.	2.5	12
125	Heterogeneity of respiratory disease in children and young adults with sickle cell disease. Thorax, 2018, 73, 575-577.	5.6	12
126	The significance of inadequate transcranial Doppler studies in children with sickle cell disease. PLoS ONE, 2017, 12, e0181681.	2.5	12

#	Article	IF	Citations
127	Epstein-Barr virusâ€“related post-transplant lymphoproliferative disorder with t(9;14)(p11â^¼12;q32). Cancer Genetics and Cytogenetics, 2003, 142, 134-136.	1.0	11
128	Direct and simultaneous determination of 5â€aminolaevulinic acid and porphobilinogen in urine by hydrophilic interaction liquid chromatographyâ€“electrospray ionisation/tandem mass spectrometry. Biomedical Chromatography, 2012, 26, 1033-1040.	1.7	11
129	Airway and alveolar nitric oxide production, lung function, and pulmonary blood flow in sickle cell disease. Pediatric Research, 2016, 79, 313-317.	2.3	11
130	Dehydrated hereditary stomatocytosis is associated with neonatal hepatitis. British Journal of Haematology, 2004, 126, 272-276.	2.5	10
131	Triose phosphate isomerase deficiency associated with two novel mutations in TPI gene. European Journal of Haematology, 2010, 85, 170-173.	2.2	10
132	Acute human parvovirus B19 infection and nephrotic syndrome in patients with sickle cell disease. British Journal of Haematology, 2010, 149, 289-291.	2.5	10
133	Changing Pattern of Hospital Admissions of Children With Sickle Cell Disease Over the Last 50 Years. Journal of Pediatric Hematology/Oncology, 2011, 33, 491-495.	0.6	10
134	Costâ€effectiveness analysis of preoperative transfusion in patients with sickle cell disease using evidence from the <scp>TAPS</scp> trial. European Journal of Haematology, 2014, 92, 249-255.	2.2	10
135	Prevention of Morbidity in sickle cell disease - qualitative outcomes, pain and quality of life in a randomised cross-over pilot trial of overnight supplementary oxygen and auto-adjusting continuous positive airways pressure (POMS2a): study protocol for a randomised controlled trial. Trials, 2015, 16, 376.	1.6	10
136	Genotype-phenotype association analysis identifies the role of Î± globin genes in modulating disease severity of Î² thalassaemia intermedia in Sri Lanka. Scientific Reports, 2019, 9, 10116.	3.3	10
137	Clinical management of sickle cell liver disease in children and young adults. Archives of Disease in Childhood, 2021, 106, 315-320.	1.9	10
138	Genome wide association study of silent cerebral infarction in sickle cell disease (HbSS and HbSC). Haematologica, 2021, 106, 1770-1773.	3.5	10
139	Is routine molecular screening for common Î±-thalassaemia deletions necessary as part of an antenatal screening programme?. Journal of Medical Screening, 2007, 14, 60-61.	2.3	9
140	Oxygen gradient ektacytometry does not predict pain in children with sickle cell anaemia. British Journal of Haematology, 2022, 197, 609-617.	2.5	9
141	Prasugrel hydrochloride for the treatment of sickle cell disease. Expert Opinion on Investigational Drugs, 2017, 26, 865-872.	4.1	8
142	High body mass index in children with sickle cell disease: a retrospective single-centre audit. BMJ Paediatrics Open, 2018, 2, e000302.	1.4	8
143	Geographic Differences in Phenotype and Treatment of Children with Sickle Cell Anemia from the Multinational DOVE Study. Journal of Clinical Medicine, 2019, 8, 2009.	2.4	8
144	Higher oxygen saturation with hydroxyurea in paediatric sickle cell disease. Archives of Disease in Childhood, 2020, 105, 575-579.	1.9	8

#	Article	IF	Citations
145	Genetic Analysis of Patients With Sickle Cell Anemia and Stroke Before 4 Years of Age Suggest an Important Role for Apoliprotein E. Circulation Genomic and Precision Medicine, 2020, 13, 531-540.	3.6	8
146	Sickle cell disease: Status with particular reference to India. Indian Journal of Medical Research, 2016, 143, 675.	1.0	8
147	Venous cerebral blood flow quantification and cognition in patients with sickle cell anemia. Journal of Cerebral Blood Flow and Metabolism, 2022, , 0271678X2110723.	4.3	8
148	Automating Pitted Red Blood Cell Counts Using Deep Neural Network Analysis: A New Method for Measuring Splenic Function in Sickle Cell Anaemia. Frontiers in Physiology, 2022, 13, 859906.	2.8	8
149	Individual Watershed Areas in Sickle Cell Anemia: An Arterial Spin Labeling Study. Frontiers in Physiology, 2022, 13, 865391.	2.8	8
150	The Genetic Basis of the Interaction Between Pyrimidine 5â€² Nucleotidase I Deficiency and Hemoglobin E. Nucleosides, Nucleotides and Nucleic Acids, 2004, 23, 1261-1263.	1.1	7
151	Prasugrel for Sickle Cell Vaso-Occlusive Events. New England Journal of Medicine, 2016, 375, 185-186.	27.0	7
152	Are the risks of treatment to cure a child with severe sickle cell disease too high?. BMJ: British Medical Journal, 2017, 359, j5250.	2.3	7
153	The effects of hydroxycarbamide on the plasma proteome of children with sickle cell anaemia. British Journal of Haematology, 2019, 186, 879-886.	2.5	7
154	The effect of the antisickling compoundGBT1118 on the permeability of red blood cells from patients with sickle cell anemia. Physiological Reports, 2019, 7, e14027.	1.7	7
155	Hydroxyurea and blood transfusion therapy for Sickle cell disease in South Asia: inconsistent treatment of a neglected disease. Orphanet Journal of Rare Diseases, 2021, 16, 148.	2.7	7
156	The EHA Research Roadmap: Anemias. HemaSphere, 2021, 5, e607.	2.7	7
157	The erythrocyte membrane properties of beta thalassaemia heterozygotes and their consequences for Plasmodium falciparum invasion. Scientific Reports, 2022, 12, .	3.3	7
158	The pleiotropic effects of Î±â€thalassemia on <scp>HbSS</scp> and <scp>HbSC</scp> sickle cell disease: Reduced erythrocyte cation coâ€transport activity, serum erythropoietin, and transfusion burden, do not translate into increased survival. American Journal of Hematology, 0, , .	4.1	7
159	Lung gas transfer in children with sickle cell anaemia. Respiratory Physiology and Neurobiology, 2007, 158, 70-74.	1.6	6
160	Sickle cell disease in Sri Lanka: clinical and molecular basis and the unanswered questions about disease severity. Orphanet Journal of Rare Diseases, 2020, 15, 177.	2.7	6
161	Oxidative status in the Î²-thalassemia syndromes in Sri Lanka; a cross-sectional survey. Free Radical Biology and Medicine, 2021, 166, 337-347.	2.9	6
162	Sickle cell disease: More than a century of progress. Where do we stand now?. Indian Journal of Medical Research, 2021, 154, 4.	1.0	6

#	Article	IF	Citations
163	Factor V Leiden Mutation Screened by PCR and Detected with Lanthanide-Labeled Probes. Genetic Testing and Molecular Biomarkers, 2001, 5, 291-297.	1.7	5
164	Diagnosis and management of congenital haemolytic anaemia. Clinical Medicine, 2007, 7, 625-629.	1.9	5
165	Stroke prevention in the young child with sickle cell anaemia. Annals of Hematology, 2009, 88, 943-946.	1.8	5
166	Comparison of pulse oximetry and earlobe blood gas with CO-oximetry in children with sickle cell disease: a retrospective review. BMJ Paediatrics Open, 2020, 4, e000690.	1.4	5
167	A novel index to evaluate ineffective erythropoiesis in hematological diseases offers insights into sickle cell disease. Haematologica, 2021, , .	3.5	5
168	Morbidity pattern of sickle cell disease in India: a single centre perspective. Indian Journal of Medical Research, 2013, 138, 288-90.	1.0	5
169	Initial Safety and Efficacy Results from the Phase II, Multicenter, Open-Label Solace-Kids Trial of Crizanlizumab in Adolescents with Sickle Cell Disease (SCD). Blood, 2021, 138, 12-12.	1.4	5
170	Diagnosis of plasma cell leukaemia: findings of the UK NEQAS for Leucocyte Immunophenotyping scheme. International Journal of Laboratory Hematology, 2004, 26, 37-42.	0.2	4
171	Orbital Compression Syndrome in Sickle Cell Crisis. Klinische Padiatrie, 2009, 221, 308-309.	0.6	4
172	To begin at the beginning: sickle cell disease in Africa. Lancet Haematology,the, 2014, 1, e50-e51.	4.6	4
173	The super sickling haemoglobin HbSâ€Oman: a study of red cell sickling, K⁺ permeability and associations with disease severity in patients heterozygous for HbA and HbSâ€Oman (HbA/Sâ€Oman) Tj ETQq1 1 0.784314 rgBT /Ov	2.7	
174	Lipid metabolism in terminal erythropoiesis. Blood, 2018, 131, 2872-2874.	1.4	4
175	The role of WNK in modulation of KCl cotransport activity in red cells from normal individuals and patients with sickle cell anaemia. Pflugers Archiv European Journal of Physiology, 2019, 471, 1539-1549.	2.8	4
176	Beneficial effects of adenotonsillectomy in children with sickle cell disease. ERJ Open Research, 2020, 6, 00071-2020.	2.6	4
177	Improving the laboratory diagnosis of pyruvate kinase deficiency. British Journal of Haematology, 2021, 193, 994-1000.	2.5	4
178	Eighteen-Month Interim Analysis of Efficacy and Safety of Givosiran, an RNAi Therapeutic for Acute Hepatic Porphyria, in the Envision Open Label Extension. Blood, 2020, 136, 13-13.	1.4	4
179	A SECOND CASE OF Hb RENERT [Î²133(H11)Val â†' Ala]. Hemoglobin, 2001, 25, 337-340.	0.8	3
180	Hydroxycarbamide and erythropoietin in the preoperative management of children with sickle cell anaemia undergoing moderate risk surgery. British Journal of Haematology, 2009, 144, 453-454.	2.5	3

#	Article	IF	Citations
181	Managing the burden of sickle-cell disease in Africa. Lancet Haematology,the, 2014, 1, e11-e12.	4.6	3
182	Nocturnal enuresis and K+ transport in red blood cells from patients with sickle cell anemia. Haematologica, 2016, 101, e469-e472.	3.5	3
183	Index of Pain Experience in Sickle Cell Anaemia (<scp>IPESCA</scp>): development from daily pain diaries and initial findings from use with children and adults with sickle cell anaemia. British Journal of Haematology, 2019, 186, 360-363.	2.5	3
184	National comparative audit of blood transfusion: 2014 audit of transfusion services and practice in children and adults with sickle cell disease. Transfusion Medicine, 2020, 30, 186-195.	1.1	3
185	Long-term oxygen therapy in children with sickle cell disease and hypoxaemia. Archives of Disease in Childhood, 2021, 106, 258-262.	1.9	3
186	Double-Blind, Randomized Study of Canakinumab Treatment in Pediatric and Young Adult Patients with Sickle Cell Anemia. Blood, 2019, 134, 615-615.	1.4	3
187	Interim Data from a Randomized, Placebo Controlled, Phase 1 Study of Aln-AS1, an Investigational RNAi Therapeutic for the Treatment of Acute Hepatic Porphyria. Blood, 2016, 128, 2318-2318.	1.4	3
188	Lung Clearance Index May Detect Early Peripheral Lung Disease in Sickle Cell Anemia. Annals of the American Thoracic Society, 2022, , .	3.2	3
189	Measurement of erythrocyte membrane mannoses to assess splenic function. British Journal of Haematology, 2022, , .	2.5	3
190	Update on the diagnosis and management of the autosomal dominant acute hepatic porphyrias. Journal of Clinical Pathology, 2022, 75, 537-543.	2.0	3
191	The use of <scp>nextâ€generation</scp> sequencing in the diagnosis of rare inherited anaemias: A Joint BSH/EHA Good Practice Paper*. British Journal of Haematology, 2022, 198, 459-477.	2.5	3
192	The safety and efficacy of hydroxycarbamide in infants with sickle cell anemia. Expert Review of Hematology, 2011, 4, 407-409.	2.2	2
193	Newborn screening for haematological disorders. Paediatrics and Child Health (United Kingdom), 2013, 23, 472-479.	0.4	2
194	The effect of xanthine oxidase and hypoxanthine on the permeability of red cells from patients with sickle cell anemia. Physiological Reports, 2018, 6, e13626.	1.7	2
195	Hydroxyurea: coming to conclusions on safety. Blood, 2021, 137, 728-729.	1.4	2
196	Born to clot: the European burden. British Journal of Haematology, 1999, 105, 564-566.	2.5	2
197	Prevention of Morbidity in Sickle Cell Disease (POMS 2): A Pilot Study of Nocturnal Respiratory Support Shows That Auto-Adjusting Positive Airways Pressure Is Safe and Is Preferred to Oxygen Therapy. Blood, 2015, 126, 993-993.	1.4	2
198	Study of montelukast in children with sickle cell disease (SMILES): a study protocol for a randomised controlled trial. Trials, 2021, 22, 690.	1.6	2

#	Article	IF	Citations
199	A Comprehensive Next Generation Sequencing Gene Panel Focused on Unexplained Anemia. Blood, 2015, 126, 946-946.	1.4	2
200	Use of splenic ultrasound: a new wave for immune thrombocytopenic purpura.. Journal of Clinical Pathology, 1994, 47, 414-417.	2.0	1
201	Peak expiratory flow in Afroâ€Caribbean children with and without sickle cell anaemia. Acta Paediatrica, International Journal of Paediatrics, 2007, 96, 1308-1310.	1.5	1
202	Commentary on sickle cell nonâ€invasive prenatal testing article. British Journal of Haematology, 2020, 190, 20-21.	2.5	1
203	Pathophysiological Relevance of Renal Medullary Conditions on the Behaviour of Red Cells From Patients With Sickle Cell Anaemia. Frontiers in Physiology, 2021, 12, 653545.	2.8	1
204	What is the role of chest Xâ€ray imaging in the acute management of children with sickle cell disease?. British Journal of Haematology, 2021, , .	2.5	1
205	Rituximab in Children with Autoimmune Thrombocytopenia Complicating Underlying Congenital or Acquired Immunodeficiency State.. Blood, 2006, 108, 3977-3977.	1.4	1
206	A Novel Alpha Specrtin Mutation Causing Severe Innefective Erythropoiesis. Blood, 2014, 124, 4002-4002.	1.4	1
207	What does the term â€˜sickle cell diseaseâ€™ mean?. British Journal of Haematology, 2022, 197, 381-382.	2.5	1
208	Neonatal screening for haematological disorders. Paediatrics and Child Health (United Kingdom), 2009, 19, 372-376.	0.4	0
209	The haemoglobinopathies. , 2014, , 550-559.		0
210	Extracranial internal carotid artery stenosis in children with sickle cell disease â€“ Which transducer, what measurement?. Ultrasound, 2016, 24, 86-93.	0.7	0
211	Newborn screening for haematological disorders. Paediatrics and Child Health (United Kingdom), 2017, 27, 500-505.	0.4	0
212	A Sri Lankan girl with a new genetic variant in the PKLR gene causing pyruvate kinase deficiency: a case report. Journal of Medical Case Reports, 2021, 15, 374.	0.8	0
213	Pitfalls in the Diagnosis of Î²-Thalassemia Intermedia. Hemoglobin, 2021, 45, 1-4.	0.8	0
214	Introduction of Routine Screening for Cerebrovascular Abnormailities in Sickle Cell Disease (SCD) Using Transcranial Doppler Ultrasonography (TCD).. Blood, 2005, 106, 3786-3786.	1.4	0
215	The Impact of Local Air Quality on the Number of Hospital Admissions with Acute Pain in Sickle Cell Disease within an Urban Environment.. Blood, 2006, 108, 3790-3790.	1.4	0
216	Cell Free Fetal and Total DNA Levels in Pregnancies at Risk of Sickle Cell Disease and Significant Ethnic Variation.. Blood, 2006, 108, 3791-3791.	1.4	0

#	Article	IF	Citations
217	Extracranial Internal Carotid Arterial Disease in Children with Sickle Cell Disease.. Blood, 2009, 114, 2560-2560.	1.4	0
218	Addition of Hydroxyurea to Transfusion Programme to Treat Progressive Cerebral Vasculopathy. Blood, 2010, 116, 4813-4813.	1.4	0
219	Study Design and Initial Baseline Characteristics in Solace-Kids: Crizanlizumab in Pediatric Patients with Sickle Cell Disease. Blood, 2020, 136, 22-24.	1.4	0